Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNTH NASDAQ:MTSR NASDAQ:PCVX NASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$55.15-0.3%$67.66$47.25▼$118.21$3.73B0.152.57 million shs883,949 shsMTSRMetsera$35.66-1.5%$34.43$12.30▼$47.40$3.71BN/A1.28 million shs1.81 million shsPCVXVaxcyte$32.10+1.7%$33.22$27.66▼$121.06$4.10B1.041.47 million shs1.43 million shsPHVSPharvaris$21.91-2.6%$21.17$11.51▼$26.33$1.13B-2.8110,290 shs73,840 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus-0.25%-2.97%-22.82%-31.35%-47.69%MTSRMetsera-1.52%+1.83%+3.54%+24.38%+3,565,999,900.00%PCVXVaxcyte+1.71%+5.07%-4.80%-7.76%-70.86%PHVSPharvaris-2.62%-7.86%+3.15%+36.51%+24.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLNTHLantheus4.8872 of 5 stars4.33.00.04.23.42.51.9MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/APCVXVaxcyte2.7844 of 5 stars3.63.00.00.03.61.70.0PHVSPharvaris2.8333 of 5 stars3.45.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNTHLantheus 2.67Moderate Buy$91.6066.09% UpsideMTSRMetsera 3.00Buy$59.0065.45% UpsidePCVXVaxcyte 3.13Buy$130.00304.98% UpsidePHVSPharvaris 2.83Moderate Buy$35.6062.48% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, LNTH, PCVX, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025MTSRMetseraCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight8/28/2025MTSRMetseraBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $50.008/18/2025PHVSPharvarisZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/13/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$55.00 ➝ $52.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/7/2025PCVXVaxcyteCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$120.00 ➝ $70.007/16/2025LNTHLantheusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform6/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNTHLantheus$1.53B2.44$7.13 per share7.74$17.16 per share3.21MTSRMetseraN/AN/AN/AN/A$4.28 per shareN/APCVXVaxcyteN/AN/AN/AN/A$23.66 per shareN/APHVSPharvarisN/AN/AN/AN/A$4.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNTHLantheus$312.44M$3.7614.678.74N/A17.82%34.06%19.10%11/5/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/APCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)PHVSPharvaris-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)Latest PHVS, LNTH, PCVX, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PHVSPharvaris-$0.87-$0.94-$0.07-$0.94N/AN/A8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLNTHLantheusN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNTHLantheus0.494.294.07MTSRMetseraN/A5.265.26PCVXVaxcyteN/A11.1111.11PHVSPharvarisN/A8.338.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNTHLantheus99.06%MTSRMetseraN/APCVXVaxcyte96.78%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipLNTHLantheus2.00%MTSRMetseraN/APCVXVaxcyte3.10%PHVSPharvarisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNTHLantheus70067.99 million66.63 millionOptionableMTSRMetsera81105.06 millionN/AN/APCVXVaxcyte160129.82 million125.80 millionOptionablePHVSPharvaris3052.29 millionN/ANot OptionablePHVS, LNTH, PCVX, and MTSR HeadlinesRecent News About These CompaniesPharvaris N.V. (NASDAQ:PHVS) Receives $35.60 Consensus PT from BrokeragesAugust 28, 2025 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Stock Price Up 5.9% - What's Next?August 27, 2025 | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAugust 27, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Upgraded to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 6.2% - Here's What HappenedAugust 21, 2025 | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Short Interest UpdateAugust 20, 2025 | marketbeat.comPharvaris Advances Clinical Pipeline with Strong FinancialsAugust 20, 2025 | msn.comWhat is Leerink Partnrs' Estimate for Pharvaris Q3 Earnings?August 19, 2025 | marketbeat.comCantor Fitzgerald Increases Earnings Estimates for PharvarisAugust 17, 2025 | marketbeat.comWedbush Comments on Pharvaris' Q3 Earnings (NASDAQ:PHVS)August 17, 2025 | marketbeat.comWedbush Predicts Pharvaris' FY2029 Earnings (NASDAQ:PHVS)August 16, 2025 | marketbeat.comJMP Securities Lowers Pharvaris (NASDAQ:PHVS) Price Target to $52.00August 15, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPSAugust 14, 2025 | marketbeat.comPharvaris price target lowered to $52 from $55 at Citizens JMPAugust 13, 2025 | msn.comPharvaris Reports Q2 2025 Financials and Advances Phase 3 StudiesAugust 12, 2025 | msn.comPharvaris Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | taiwannews.com.twTPharvaris Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comPharvaris (PHVS) Projected to Post Earnings on WednesdayAugust 6, 2025 | marketbeat.comTD Asset Management Inc Has $1.23 Million Holdings in Pharvaris N.V. (NASDAQ:PHVS)August 4, 2025 | marketbeat.comPharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutionsJuly 27, 2025 | finance.yahoo.comPharvaris secures $175 million public offeringJuly 25, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, LNTH, PCVX, and MTSR Company DescriptionsLantheus NASDAQ:LNTH$55.15 -0.14 (-0.25%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$55.72 +0.57 (+1.03%) As of 09/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Metsera NASDAQ:MTSR$35.66 -0.55 (-1.52%) As of 09/3/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Vaxcyte NASDAQ:PCVX$32.10 +0.54 (+1.71%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$32.45 +0.35 (+1.09%) As of 09/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Pharvaris NASDAQ:PHVS$21.91 -0.59 (-2.62%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$22.10 +0.20 (+0.89%) As of 09/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
